The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Open accessAbstract
BACKGROUND: Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis. METHODS: In this phase 3, double-blind, placebo-controlled, parallel-group, 6-month study, 611 patients were randomly assigned, in a 4:4:1:1 ratio, to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, placebo for 3 months followed by 5 mg of tofacitinib twice daily, or placebo for 3 months followed by 10 mg of tofacitinib twice daily. The primary end points, assessed at month 3, were the percentage of patients with at least a 20% improvement in the American College of Rheumatology scale (ACR 20), the change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) scores (which range from 0 to 3, with higher scores indicating greater disability), and the percentage of patients with a Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4[ESR]) of less than 2.6 (with scores ranging from 0 to 9.4 and higher scores indicating more disease activity). RESULTS: At month 3, a higher percentage of patients in the tofacitinib groups than in the placebo groups met the criteria for an ACR 20 response (59.8% in the 5-mg tofacitinib group and 65.7% in the 10-mg tofacitinib group vs. 26.7% in the combined placebo groups, P<0.001 for both comparisons). The reductions from baseline in HAQ-DI scores were greater in the 5-mg and 10-mg tofacitinib groups than in the placebo groups (-0.50 and -0.57 points, respectively, vs. -0.19 points; P<0.001). The percentage of patients with a DAS28-4(ESR) of less than 2.6 was not significantly higher with tofacitinib than with placebo (5.6% and 8.7% in the 5-mg and 10-mg tofacitinib groups, respectively, and 4.4% with placebo; P=0.62 and P=0.10 for the two comparisons). Serious infections developed in six patients who were receiving tofacitinib. Common adverse events were headache and upper respiratory tract infection. Tofacitinib treatment was associated with elevations in low-density lipoprotein cholesterol levels and reductions in neutrophil counts. CONCLUSIONS: In patients with active rheumatoid arthritis, tofacitinib monotherapy was associated with reductions in signs and symptoms of rheumatoid arthritis and improvement in physical function. (Funded by Pfizer; ORAL Solo ClinicalTrials.gov number, NCT00814307.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.
Fries, J. F., Spitz, P. W., & Young, D. Y. (1982) · PubMed · Cited by 1,318
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Self-citationHochberg, M. C., Chang, R. W., Dwosh, I., Lindsey, S., Pincus, T., & Wolfe, F. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350502 · Cited by 879
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Kremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Self-citationWolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22864 · Cited by 534
Cited by
Smolen, J. S., Aletaha, D., & McInnes, I. B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30173-8 · Cited by 4,870
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Singh, J. A., Furst, D. E., Bharat, A., Curtis, J. R., Kavanaugh, A. F., Kremer, J. M., Moreland, L. W., O'Dell, J., Winthrop, K. L., Beukelman, T., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21641 · Cited by 1,789
Self-citationSmolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,763
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22783 · Cited by 1,107
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
Schett, G., & Gravallese, E. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.153 · Cited by 947
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Self-citationJAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro
Benam, K. H., Villenave, R., Lucchesi, C., Varone, A., Hubeau, C., Lee, H.-H., Alves, S. E., Salmon, M., Ferrante, T. C., Weaver, J. C., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3697 · Cited by 816
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
Validating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712
Tofacitinib versus methotrexate in rheumatoid arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711
Self-citationBulten, W., Pinckaers, H., van Boven, H., Vink, R., de Bel, T., van Ginneken, B., van der Laak, J., Hulsbergen-van de Kaa, C., & Litjens, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30739-9 · Cited by 705
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., Cardiel, M. H., Cohen, S., Nash, P., Song, Y., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37816 · Cited by 577
Self-citationTofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Gladman, D., Rigby, W., Azevedo, V. F., Behrens, F., Blanco, R., Kaszuba, A., Kudlacz, E., Wang, C., Menon, S., Hendrikx, T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615977 · Cited by 510
Self-citationFleischmann, R., Mysler, E., Hall, S., Kivitz, A. J., Moots, R. J., Luo, Z., DeMasi, R., Soma, K., Zhang, R., Takiya, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31618-5 · Cited by 499
Self-citationJanus kinase inhibitors in autoimmune diseases
O'Shea, J. J., Kontzias, A., Yamaoka, K., Tanaka, Y., & Laurence, A. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202576 · Cited by 453
The ‘cytokine storm’: molecular mechanisms and therapeutic prospects
Karki, R., & Kanneganti, T.-D. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.06.001 · Cited by 438
Bachelez, H., van de Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.-H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62113-9 · Cited by 410
Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.267 · Cited by 394
Cohen, S. B., Tanaka, Y., Mariette, X., Curtis, J. R., Lee, E. B., Nash, P., Winthrop, K. L., Charles-Schoeman, C., Thirunavukkarasu, K., DeMasi, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210457 · Cited by 393
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C.-H., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 383
Smolen, J. S., Pangan, A. L., Emery, P., Rigby, W., Tanaka, Y., Vargas, J. I., Zhang, Y., Damjanov, N., Friedman, A., Othman, A. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30419-2 · Cited by 379
van der Heijde, D., Deodhar, A., Wei, J. C., Drescher, E., Fleishaker, D., Hendrikx, T., Li, D., Menon, S., & Kanik, K. S. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210322 · Cited by 376
Self-citationHerpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Winthrop, K. L., Yamanaka, H., Valdez, H., Mortensen, E., Chew, R., Krishnaswami, S., Kawabata, T., & Riese, R. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38745 · Cited by 353
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Liu, L. Y., Craiglow, B. G., Dai, F., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.09.007 · Cited by 349
A Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
Heine, A., Held, S. A. E., Daecke, S. N., Wallner, S., Yajnanarayana, S. P., Kurts, C., Wolf, D., & Brossart, P. (2013) · Blood · doi:10.1182/blood-2013-03-484642 · Cited by 344
Olivera, P. A., Lasa, J. S., Bonovas, S., Danese, S., & Peyrin-Biroulet, L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.001 · Cited by 330
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
Coskun, M., Salem, M., Pedersen, J., & Nielsen, O. H. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.06.007 · Cited by 325
Wollenhaupt, J., Lee, E.-B., Curtis, J. R., Silverfield, J., Terry, K., Soma, K., Mojcik, C., DeMasi, R., Strengholt, S., Kwok, K., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1866-2 · Cited by 320
Di Meglio, P., Villanova, F., & Nestle, F. O. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015354 · Cited by 317
Therapeutic advances in rheumatoid arthritis
Brown, P., Pratt, A. G., & Hyrich, K. L. (2024) · BMJ · doi:10.1136/bmj-2022-070856 · Cited by 312
Familial chilblain lupus due to a gain-of-function mutation in STING
König, N., Fiehn, C., Wolf, C., Schuster, M., Cura Costa, E., Tüngler, V., Alvarez, H. A., Chara, O., Engel, K., Goldbach-Mansky, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209841 · Cited by 308
Choy, E., Ganeshalingam, K., Semb, A. G., Szekanecz, Z., & Nurmohamed, M. (2014) · Rheumatology · doi:10.1093/rheumatology/keu224 · Cited by 303
LGL leukemia: from pathogenesis to treatment
Lamy, T., Moignet, A., & Loughran, T. P. (2017) · Blood · doi:10.1182/blood-2016-08-692590 · Cited by 302
Tofacitinib: A Review in Rheumatoid Arthritis
Dhillon, S. (2017) · Drugs · doi:10.1007/s40265-017-0835-9 · Cited by 302
The role of the JAK/STAT signal pathway in rheumatoid arthritis
Malemud, C. J. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18776224 · Cited by 302
Wollenhaupt, J., Silverfield, J., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D., Nakamura, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130683 · Cited by 301
Self-citationThe JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
Boyle, D. L., Soma, K., Hodge, J., Kavanaugh, A., Mandel, D., Mease, P., Shurmur, R., Singhal, A. K., Wei, N., Rosengren, S., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206028 · Cited by 300
Self-citationA Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Wang, W., Niezychowski, W., Vermeire, S. A. R. A., Dewit, O., Peeters, H., Stehlik, J., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.029 · Cited by 300
Schiff, M., Weinblatt, M. E., Valente, R., van der Heijde, D., Citera, G., Elegbe, A., Maldonado, M., & Fleischmann, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203843 · Cited by 293
Self-citationT cell migration in rheumatoid arthritis
Mellado, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00384 · Cited by 291
Bechman, K., Subesinghe, S., Norton, S., Atzeni, F., Galli, M., Cope, A. P., Winthrop, K. L., & Galloway, J. B. (2019) · Rheumatology · doi:10.1093/rheumatology/kez087 · Cited by 287
Curtis, J. R., Xie, F., Yun, H., Bernatsky, S., & Winthrop, K. L. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209131 · Cited by 285
Clinical significance of Janus Kinase inhibitor selectivity
Choy, E. H. (2019) · Rheumatology · doi:10.1093/rheumatology/key339 · Cited by 285
Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P.-Y., Lee, C. H., Fidelus-Gort, R. K., Luchi, M. E., Rooney, T. P., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206478 · Cited by 281
Covalent docking of large libraries for the discovery of chemical probes
London, N., Miller, R. M., Krishnan, S., Uchida, K., Irwin, J. J., Eidam, O., Gibold, L., Cimermančič, P., Bonnet, R., Shoichet, B. K., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1666 · Cited by 274
The next generation of therapeutics for chronic kidney disease
Breyer, M. D., & Susztak, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.67 · Cited by 272
Mease, P. J., & Armstrong, A. W. (2014) · Drugs · doi:10.1007/s40265-014-0191-y · Cited by 271
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm
Robertson, J., Peters, M. J., McInnes, I. B., & Sattar, N. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.91 · Cited by 264
Strazzulla, L. C., Wang, E. H. C., Avila, L., Lo Sicco, K., Brinster, N., Christiano, A. M., & Shapiro, J. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.04.1142 · Cited by 263
Deodhar, A., Sliwinska-Stanczyk, P., Xu, H., Baraliakos, X., Gensler, L. S., Fleishaker, D., Wang, L., Wu, J., Menon, S., Wang, C., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219601 · Cited by 259
Self-citationDas, R., Guan, P., Sprague, L., Verbist, K., Tedrick, P., An, Q. A., Cheng, C., Kurachi, M., Levine, R., Wherry, E. J., et al. (2016) · Blood · doi:10.1182/blood-2015-12-684399 · Cited by 254
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases
Patterson, H., Nibbs, R., McInnes, I., & Siebert, S. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12248 · Cited by 199
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
Winthrop, K. L., Silverfield, J., Racewicz, A., Neal, J., Lee, E. B., Hrycaj, P., Gomez-Reino, J., Soma, K., Mebus, C., Wilkinson, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207191 · Cited by 196
Next generation of small molecules in inflammatory bowel disease
Olivera, P., Danese, S., & Peyrin-Biroulet, L. (2017) · Gut · doi:10.1136/gutjnl-2016-312912 · Cited by 154
Adcock, I. M., & Mumby, S. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_98 · Cited by 131
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Zhou, M., Yang, H., Learned, R. M., Tian, H., & Ling, L. (2017) · Nature Communications · doi:10.1038/ncomms15433 · Cited by 123
Back to the future: oral targeted therapy for RA and other autoimmune diseases
O'Shea, J. J., Laurence, A., & McInnes, I. B. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.7 · Cited by 115
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
Núñez, P., Quera, R., & Yarur, A. J. (2023) · Drugs · doi:10.1007/s40265-023-01840-5 · Cited by 111
Are Janus kinase inhibitors superior over classic biologic agents in RA patients?
Kotyla, P. J. (2018) · BioMed Research International · doi:10.1155/2018/7492904 · Cited by 47
“Phase III trials confirmed observations driven from phase II [75].”
Background
Metadata
- Authors
- Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-08-09
- Volume
- 367
- Issue
- 6
- Pages
- 495-507
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2153414586
- Cited by
- 1,024
- References
- 17
- FWCI
- 51.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.